Canadian Pacific Kansas City Limited Common Shares vs Neurocrine Biosciences Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.71B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 5× Neurocrine Biosciences Inc's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.91% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CP | NBIX | |
|---|---|---|
Market Cap | $73.71B | $14.60B |
Volume | 2,143,178 | 1,075,694 |
Sector | Industrials | Health |
52-Week High | $96.69 | $185.50 |
52-Week Low | $68.88 | $123.10 |
Enterprise Value | $91.14B | $14.61B |
Dividend Yield | 0.91% | — |
Typical Hold Time | — | 23 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Trailing returns across standard periods
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →